-
公开(公告)号：DE3841755A1
公开(公告)日：1990-06-13
申请号：DE3841755
申请日：1988-12-12
Applicant: BASF AG
Inventor： BOEHM HANS-JOACHIM DR , DAUM LOTHAR DR , HAUPT ANDREAS DR , SCHMIED BERNHARD DR , WALKER NIGEL DR , ZECHEL JOHANN-CHRISTIAN DR
IPC: A61K38/00 , A61P29/00 , A61P35/00 , A61P37/06 , C07K1/04 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/52 , C07K14/525
Abstract: New peptides of formula x-Ala-His-A-Y, in which A, X and Y have the meanings given in the description, are useful therapeutic agents. A process for producing them is also described.
-
公开(公告)号：DE3841754A1
公开(公告)日：1990-06-13
申请号：DE3841754
申请日：1988-12-12
Applicant: BASF AG
Inventor： BOEHM HANS-JOACHIM DR , DAUM LOTHAR DR , HAUPT ANDREAS DR , SCHMIED BERNHARD DR , WALKER NIGEL DR , ZECHEL JOHANN-CHRISTIAN DR
IPC: A61K38/00 , A61P29/00 , A61P35/00 , A61P37/06 , C07K1/04 , C07K7/06 , C07K7/08 , C07K7/64 , C07K14/00 , C07K14/52 , C07K14/525
Abstract: New peptides of formula X-A-Y, in which A, X and Y have the meanings given in the description, are useful therapeutic agents. A process for producing them is also described.
-
公开(公告)号：CZ288448B6
公开(公告)日：2001-06-13
申请号：CZ326096
申请日：1995-04-26
Applicant: BASF AG
Inventor： AMBERG WILHELM DR , BERNARD HARALD DR , BUSCHMANN ERNST DR , HAUPT ANDREAS DR , JANITSCHKE LOTHAR DR , MUELLER STEFAN DR , DE POTZOLLI BERND DR , RITTER KURT DR , THYES MARCO DR , ZIERKE THOMAS DR , JANSSEN BERND DR , KARL ULRICH DR , KLING ANDREAS DR
Abstract: In the present invention, there is described pentapeptide hydrochloride of the formula Mei2Val-Val-MeVal-Pro-Pro-NHBz1.HCl, which is present in crystalline form. It is prepared from the compound of the formula Z-Val-Val-MeVal-Pro-ORe1, in which Z represents a benzyloxycarbonyl protecting group, which might be optionally substituted on the phenyl ring and Re1 represents alkyl containing 1 to 5 carbon atoms. In the present invention, there are also described intermediates for preparing the above indicated pentapeptide hydrochloride. The above-described compound exhibits antineoplastic activity.
-
Patent Agency Ranking24.发明专利
公开(公告)号：CZ9800243A3
公开(公告)日：1998-07-15
申请号：CZ24398
申请日：1996-07-12
Applicant: BASF AG
Inventor： AMBERG WILHELM DR , BERNARD HARALD DR , BUSCHMANN ERNST DR , HAUPT ANDREAS DR , JANSSEN BERND DR , KARL ULRICH DR , KLING ANDREAS DR , MULLER STEFAN DR , RITTER KURT DR , ZIERKE THOMAS DR
IPC: C07K1/02 , C07K1/12 , C07K5/078 , C07K5/083 , C07K5/103 , C07K7/06 , C07K5/06 , C07K5/08 , C07K5/10
CPC classification number: C07K7/06 , C07K5/06165 , C07K5/0808 , C07K5/101
-
公开(公告)号：CZ376597A3
公开(公告)日：1998-06-17
申请号：CZ376597
申请日：1996-06-03
Applicant: BASF AG
Inventor： HAUPT ANDREAS DR , EMLING FRANZ DR , ROMERDAHL CYNTHIA A DR
Abstract: Novel compounds of the formulaR1R2N-CHX-CO-A-B-D-(E)s-(F)t-(G)U-KIin which R1, R2, A, B, D, E, F, G, K, X, s, t, and u have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.
-
公开(公告)号：CZ9603260A3
公开(公告)日：1997-04-16
申请号：CZ326096
申请日：1995-04-26
Applicant: BASF AG
-
公开(公告)号：DE19527575A1
公开(公告)日：1997-01-30
申请号：DE19527575
申请日：1995-07-28
Applicant: BASF AG
Inventor： AMBERG WILHELM DR , BERNARD HARALD DR , BUSCHMANN ERNST DR , HAUPT ANDREAS DR , JANSSEN BERND DR , KARL ULRICH DR , KLING ANDREAS DR , MUELLER STEFAN DR , RITTER KURT DR , ZIERKE THOMAS DR
IPC: C07K1/02 , C07K1/12 , C07K5/06 , C07K5/078 , C07K5/08 , C07K5/083 , C07K5/10 , C07K5/103 , C07K7/06 , A61K38/08
Abstract: The description relates to a process for producing pentapeptides of the formula (I) in which A and R -R have the meanings given, in which the pentapeptide is constructed in steps from a prolinamide of the formula (II) in which R and R have the meanings given above, and the group -NR R may be hydrolytically separated from the peptide thus obtained.
-
公开(公告)号：DE4041188A1
公开(公告)日：1992-06-25
申请号：DE4041188
申请日：1990-12-21
Applicant: BASF AG
Inventor： BOEHM HANS-JOACHIM DR , DAUM LOTHAR DR , HAUPT ANDREAS DR , PETTIG DAGMAR DR , WALKER NIGEL DR , MAENNEL DANIELA DR , FRANK REINER DR , STIEHNER RAINER DR
IPC: A61K38/00 , C07K14/525
Abstract: Peptides of formula X-Leu-A-B-Asn- E-Leu-F-K-Pro-L-Y (I), derived from tumour necrosis factor (TNF), and their salts with physiologically tolerable acids are new: (where A = Arg, Glu, Thr, Lys or Ser; B = Asp or Asn; E = Gln or Ser; F = Val, Leu or NH-CHT-CO; T = HS(CH2)b, NH2(CH2)b or HOOC(CH2)b; b = 1-6; K = Val or Ile; L = Ser, Ala or Thr; X = G, GNH-CHM-CO or GNH-CHM-COW-; Y = Z, NH-CHQ-COZ, -V-NH-CHQ-COZ; NH-CHQ-CO-V-Z or V-NH-CHQ-CO-V-Z; G = H or amino-protecting gp.; Z = OH, NH2 or carboxy-protecting gp.; or G and Z are together a covalent bond or CO-(CH2)a-NH; a = 1-12; U, V and W = peptide chain with 1-4 naturally occurring amino acids; M and Q = H, CHMe2, CHMe-Et, phenyl, CHOH-Me, (3-indolyl)methyl, (imidazolyl-4-yl)methyl or (CH2)bT; b = 1-6; T = H, OH, MeO, MeS, Me2CH, phenyl (opt. 4-OH substd.), HS, NH2, COOH, CONH2 or guanidino; or M and Q or M and T are together a (CH2)c-S-S-(CH2)d-, (CH2)e-CONH-(CH2)f or (CH2)e-NHCO(CH2)gNH bridge; c and d = 1-4; e and f = 1-6; g = 1-12). (I) are obtd. by standard (chemical or enzymatic) peptide synthesis, initially as linear peptides, opt. followed by appropriate cyclisation reaction under very dilute conditions. USE/ADVANTAGE - Some (I) are TNF agonists, others are TNF antagonists (these have high affinity for cellular receptors but no activity). They are used for treating neoplastic and autoimmune diseases, and for treating or preventing infections, inflammation and transplant rejection. They have significantly lower mol. wt. than TNF.
-
-
-
-
-
-
-
Search Results
28
records
(took 0.019 seconds)
